- Fresenius Medical Care delivers on commitments during a year of
fundamental transformation
- Progress towards sustainability goals in key areas: patient
satisfaction, diversity in management, climate target roadmap
BAD HOMBURG, Germany, March 22,
2024 /PRNewswire/ -- Fresenius Medical Care (FME),
the world's leading provider of products and services for
individuals with renal diseases, today published its joint 2023
Annual Report and Non-financial Group Report, available digitally
on the corporate website. Titled "Shaping the Future of Kidney
Care," the report provides detailed information about Fresenius
Medical Care's economic, social and environmental performance in
2023.
Helen Giza, CEO and Chair of the
Management Board of Fresenius Medical Care AG, said: "The year 2023
was a transformative one for Fresenius Medical Care, as we set out
to achieve important structural, operational, and cultural changes.
I am proud to say that we successfully executed on our commitment
of fundamental transformation and made significant progress against
our financial and sustainability targets in our strategic
plan."
The 2023 Annual Report summarizes Fresenius Medical Care's steps
to successfully deliver on the transformation and contains
Fresenius Medical Care's Non-financial Group Report, providing a
comprehensive overview of its progress of sustainability activities
and achievements in three strategic focus areas:
Enhancing quality care and access to health care: In
about 4,000 dialysis clinics in around 50 countries worldwide,
Fresenius Medical Care provided care for over 332,000 patients in
2023. Underlining the company's commitment and focus on providing
high-quality care and enhancing access to health care, the
patients' overall satisfaction with its services measured by the
patient Net Promoter Score of 72 was at a slightly higher level
than in previous years (2022: Score of 71).
Building the best team to serve patients: In 2023,
fostering diversity and engagement was a key focus to building the
best team to serve patients worldwide. Fresenius Medical Care
increased the share of women in the top two management levels below
the Management Board to 34% (2022: 30%). In a step to strengthen
its commitment to diversity, the company also became a signatory
with the United Nations Women's Empowerment Principles, the German
Charter for Diversity, and the CEO Action for Diversity and
Inclusion.
Reducing its environmental footprint: Fresenius
Medical Care also made progress in line with its climate target
roadmap and expanded its environmental reporting as the company
works towards reducing its environmental footprint. The company's
reported Scope 1 and 2 emissions decreased by 16% from a 2020
baseline. Notably, Fresenius Medical Care's recent submission of
the commitment letter to the Science Based Targets Initiative
(SBTi) highlights its goal to achieve climate neutrality in
operations by 2040, which is in line with the Paris Agreement.
The Annual Report will be published digitally in accordance with
Fresenius Medical Care's dedication to environmental
sustainability. It is available for download as pdf-file on the
company's website: Annual reports | Fresenius Medical Care.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products
and services for individuals with renal diseases of which around
4.1 million patients worldwide regularly undergo dialysis
treatment. Through its network of 4,000 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approximately 332,000
patients around the globe and is the leading provider of dialysis
products such as dialysis machines and dialyzers. Fresenius Medical
Care is listed on the Frankfurt Stock Exchange (FME) and on the New
York Stock Exchange (FMS).
For more information visit the Company's website
at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to the COVID-19 pandemic
results of clinical studies, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties
are detailed in Fresenius Medical Care's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care
does not undertake any responsibility to update the forward-looking
statements in this release.
Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-publishes-2023-joint-annual-report-and-sustainability-report-shaping-the-future-of-kidney-care-302096575.html
SOURCE Fresenius Medical Care Holdings, Inc.
